AstraZeneca
AZNH
AZNH was delisted on the 29th of January, 2026.
1 hedge funds and large institutions have $3.63M invested in AstraZeneca in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
135% more capital invested
Capital invested by funds: $1.55M → $3.63M (+$2.09M)
42.58% more ownership
Funds ownership: 36.75% → 79.32% (+43%)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.5K |
AZNH Hedge Fund Activity: Q1 2025 in Review
1 of the 7,477 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZNH) for Q1 2025, worth a combined $3.63M — up 135% from $1.55M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AZNH and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $1.96M. The largest seller was UBS Group, exiting entirely with an estimated $4.5K sold.
- 1 institutional investor held AstraZeneca (AZNH) as of Q1 2025, down from 2 in Q4 2024.
- Funds reported $3.63M of AstraZeneca stock for Q1 2025, up 135% quarter-over-quarter.
- 0 funds opened new AstraZeneca positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest AstraZeneca buyer in Q1 2025 was Citadel Advisors, an estimated $1.96M added.
- The largest AstraZeneca seller in Q1 2025 was UBS Group, an estimated $4.5K sold.
Based on aggregated 13F filings for Q1 2025.